Medical/Pharmaceuticals

GORE COMPLETES FIRST IN-HUMAN IMPLANTS OF THE GORE® VIAFORT VASCULAR STENT

CAUTION: Investigational device. Limited by United States law to investigational use. W. L. Gore & Associates initiates its GORE® VIAFORT Device Pivotal Clinical Study for the treatment of inferior vena cava occlusive disease. FLAGSTAFF, Ariz., Oct. 29, 2022 /PRNewswire/ -- W. L. Gore & Associat...

2022-10-29 02:10 10124

Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022

SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy forLMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessio...

2022-10-28 22:30 3828

LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022

The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been confirmed in various animal models SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented ne...

2022-10-28 21:00 2961

Future of Healthcare Week Asia: Building sustainable systems for all

* A hybrid event unifying the public, private and civil sectors from health and technology to foster better healthcare for all and ensure continuity of care. * Speakers include Budi Gunadi Sadikin, Indonesia's Minister of Health; Kai-Fu Lee, Sinovation Ventures's chairman and chief executive;...

2022-10-28 20:32 3865

Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit

BOSTON, Oct. 28, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...

2022-10-28 20:30 3207

Stamford American celebrates Global Be Well Day, highlighting the importance of well-being

Stamford American students take time during Global Be Well Day to do stretching exercises on the sports field and dance to music. SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Well-being has been one of the most important issues facingSingapore recently, and there are signs the Lion City has begun to...

2022-10-28 14:56 3567

Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN, Netherlands, Oct. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation Application (MAA) for leni...

2022-10-28 13:00 5944

2022 Digitisation in Traditional Medicine World Summit successfully held in Macau

Joint discussion on digitisation with credit initiative between China and ASEAN countries MACAU, Oct. 28, 2022 /PRNewswire/ -- Here is the report from Macau business By Tony Lai: A conference about digitisation of the industry of Traditional Complementary Medicine (TCM) was held inMacau on Frida...

2022-10-28 11:36 1146

Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine

TAIZHOU, China, Oct. 28, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group")  is pleased to announce that, the Group has recently received a notice of acceptance from the National Medical Products Administration to accept the appli...

2022-10-28 11:10 5109

Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada

Phase 3 Trials Initiated with Tegoprazan for the Treatment of Erosive Esophagitis and Non-erosive Reflux Disease BRAINTREE, Mass., Oct. 28, 2022 /PRNewswire/ -- Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan inthe United States and C...

2022-10-28 09:00 4491

Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity

-  Mean body weight loss of 11.1% in participants receiving once-weekly injections of 2.4 mg XW003 for 18 weeks -  88.5% and 57.7% of participants receiving 2.4 mg XW003 for 18 weeks achieved weight loss of≥5% and ≥10%, respectively  -  XW003 was safe and well tolerated, with an adverse event p...

2022-10-28 08:00 3784

NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review

Fosun Kite to Participate in the Fifth CIIE to Showcase New Options in Cell Therapy SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication o...

2022-10-28 01:37 3172

hemotune Applauded by Frost & Sullivan for Enabling Selective and Efficient Extraction of Large Compounds from Blood With Its Blood Purification Platform

HemoSystem improves patient outcomes while shortening the length of stay in intensive care units, reducing the sepsis burden for patients, hospitals, and healthcare systems. SAN ANTONIO, Oct. 27, 2022 /PRNewswire/ -- Recently, Frost & Sullivan assessed the blood purification technology industry a...

2022-10-27 23:00 3173

Life sciences industry's highest achievers celebrated at prestigious Awards ceremony

AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards * Industry Leadership Award: Professors Steve Wilton AO and Sue Fletcher AO * Company of the Year: Telix Pharmaceuticals * Emerging Company of the Year: Fusetec AusBiotech Life Sciences Legacy Award: Dr Andrew Forrest AO a...

2022-10-27 22:39 6996

WuXi Biologics Provides Corporate Updates

SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its recent corporate progress. Recent Business Milestone Despite the global dynamic situation and funding challeng...

2022-10-27 22:13 3707

Mentice Launches New Website

GOTHENBURG, Sweden, Oct. 27, 2022 /PRNewswire/ -- Mentice, a world leader in virtual and physical simulation solutions for Image-guided Interventional Therapies, is pleased to announce the launch of its new websitewww.mentice.com .   Mentice is proud to present the platform's innovative design, s...

2022-10-27 22:02 2972

Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237

Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oct. 27, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovative global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the com...

2022-10-27 21:25 3233

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US

SUZHOU, China, Oct. 27, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 120 subj...

2022-10-27 21:22 3107

Medtecs to showcase its world-leading PPE solutions in Germany and France

TAIPEI, Oct. 27, 2022 /PRNewswire/ -- As countries reopen their borders for international travel with global vaccination coverage on the rise, the world is slowly returning to pre-pandemic activity levels since the COVID-19 outbreak nearly 3 years ago. Needless to say, personal protective equi...

2022-10-27 18:14 1413

Cambrex to Invest $16.5 Million in New R&D Facility in Minneapolis, Minnesota and Expansion in Charles City, Iowa

EAST RUTHERFORD, N.J., Oct. 27, 2022 /PRNewswire/ -- Cambrex today announced it is investing in a new, 21,000-square-foot research and development facility in Minneapolis, Minnesota, expanding its capacity for small molecule development and manufacturing. Strategically located near the Minneapolis...

2022-10-27 18:00 3929
1 ... 510511512513514515516 ... 643